NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
-1.68%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$120M
AUM Growth
+$120M
(+46%)
Cap. Flow
+$39.9M
Cap. Flow
% of AUM
33.26%
Top 10 Holdings %
Top 10 Hldgs %
71.57%
Holding
35
New
11
Increased
11
Reduced
1
Closed
12
Top Buys
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$11.2M |
| 2 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$6.99M |
| 3 |
Ascendis Pharma
ASND
|
$6.94M |
| 4 |
Pacira BioSciences
PCRX
|
$6.48M |
| 5 |
Neurocrine Biosciences
NBIX
|
$5.77M |
Top Sells
| 1 |
Heron Therapeutics
HRTX
|
$9.5M |
| 2 |
Bausch Health
BHC
|
$5.08M |
| 3 |
STML
Stemline Therapeutics, Inc.
STML
|
$4.18M |
| 4 |
Novartis
NVS
|
$3.83M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$2.79M |
Sector Composition
| 1 | Healthcare | 92.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $12.1M | 10.1% | 152,441 +140,489 | +1,175% | +$11.2M |
|
2
Insmed
INSM
$28.8B
| $12.1M | 10.04% | 470,741 +186,478 | +66% | +$4.77M |
|
|
BOLD
3
DELISTED
Audentes Therapeutics, Inc
BOLD
| $11.1M | 9.27% | 294,013 +43,393 | +17% | +$1.64M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $7.8M | 6.5% | 92,380 +68,340 | +284% | +$5.77M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $7.65M | 6.37% | 50,317 +29,047 | +137% | +$4.41M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $7.49M | 6.23% | 142,305 +55,206 | +63% | +$2.9M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $7.27M | 6.06% | 524,140 +189,416 | +57% | +$2.63M |
|
|
8
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $6.99M | 5.82% | +316,316 | New | +$6.99M |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $6.94M | 5.78% | +60,266 | New | +$6.94M |
|
|
10
Pacira BioSciences
PCRX
$1.2B
| $6.48M | 5.4% | +149,086 | New | +$6.48M |
|
11
UroGen Pharma
URGN
$900M
| $6.36M | 5.29% | 176,866 +44,277 | +33% | +$1.59M |
|
12
uniQure
QURE
$896M
| $4.68M | 3.9% | 59,883 +21,083 | +54% | +$1.65M |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $4.47M | 3.72% | 230,295 +81,600 | +55% | +$1.58M |
|
14
AbbVie
ABBV
$372B
| $3.83M | 3.19% | +52,681 | New | +$3.83M |
|
|
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.77M | 3.14% | +86,165 | New | +$3.77M |
|
16
Viatris
VTRS
$12.3B
| $1.95M | 1.63% | +102,560 | New | +$1.95M |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.87M | 1.55% | +143,665 | New | +$1.87M |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $1.77M | 1.48% | +5,668 | New | +$1.77M |
|
19
Madrigal Pharmaceuticals
MDGL
$9.76B
| $1.62M | 1.35% | 15,423 +11,971 | +347% | +$1.25M |
|
|
DERM
20
DELISTED
Dermira, Inc.
DERM
| $1.32M | 1.1% | +138,102 | New | +$1.32M |
|
21
Gilead Sciences
GILD
$140B
| $1.26M | 1.05% | +18,697 | New | +$1.26M |
|
22
AnaptysBio
ANAB
$569M
| $679K | 0.57% | +12,026 | New | +$679K |
|
|
AGN
23
DELISTED
Allergan plc
AGN
| $560K | 0.47% | 3,347 -10,353 | -76% | -$1.73M |
|
|
24
Bausch Health
BHC
$2.74B
| – | – | -205,660 | Closed | -$5.08M |
|
25
BioMarin Pharmaceuticals
BMRN
$11.2B
| – | – | -8,250 | Closed | -$733K |
|